Science Explorer Back to mapMap
Discussion
Company · Irving · United States

Reata Pharmaceuticals (United States)

reatapharma.comROR OpenAlex
Research works
100
▲ 14% vs 2018-21
Citations
3.2k
31.8 per fractional work
Top-10% rate
9.0%
all institutions 10.0%
Open access
47%
world 40%
International
19%
world 18%
Reata Pharmaceuticals (United States)

Not ranked overall: Reata Pharmaceuticals (United States) is under the volume floor below which a citation excellence rate is noise. Not ranked is not the same as ranked last.

Which fields of science does Reata Pharmaceuticals (United States) work in?

In 2022-now, 49% of research at Reata Pharmaceuticals (United States) is in Health Sciences, 26% in Life Sciences. Its largest fields are Medicine (49%), Biochemistry, Genetics and Molecular Biology (19%), Economics, Econometrics and Finance (11%). It does 1.8× the world's share of Health Sciences.

Health Sciences: 13 fractional works · 49.3% of its workMedicine: 12 fractional works · 48.7% of its workOncology: 3 fractional works · 11.7% of its workPulmonary and Respiratory Medicine: 3 fractional works · 10.5% of its workFamily Practice: 1 fractional works · 4.1% of its workRadiology, Nuclear Medicine and Imaging: 1 fractional works · 2.9% of its workEpidemiology: 1 fractional works · 2.5% of its workPublic Health, Environmental and Occupational Health: 0 fractional works · 2.0% of its workRheumatology: 0 fractional works · 1.6% of its workBiochemistry: 0 fractional works · 1.3% of its workGeriatrics and Gerontology: 0 fractional works · 1.3% of its workNephrology: 0 fractional works · 1.2% of its workReproductive Medicine: 0 fractional works · 1.1% of its workSurgery: 0 fractional works · 1.1% of its workComplementary and alternative medicine: 0 fractional works · 1.0% of its workOtorhinolaryngology: 0 fractional works · 1.0% of its workPathology and Forensic Medicine: 0 fractional works · 0.9% of its workImmunology and Allergy: 0 fractional works · 0.7% of its workNeurology: 0 fractional works · 0.7% of its workGenetics: 0 fractional works · 0.4% of its workDermatology: 0 fractional works · 0.4% of its workCardiology and Cardiovascular Medicine: 0 fractional works · 0.3% of its workHematology: 0 fractional works · 0.3% of its workOrthopedics and Sports Medicine: 0 fractional works · 0.3% of its workPharmacology: 0 fractional works · 0.3% of its workPhysiology: 0 fractional works · 0.3% of its workRehabilitation: 0 fractional works · 0.3% of its workGastroenterology: 0 fractional works · 0.3% of its workHealth Professions: 0 fractional works · 0.7% of its workHealth Information Management: 0 fractional works · 0.7% of its workLife Sciences: 7 fractional works · 26.2% of its workBiochemistry, Genetics and Molecular Biology: 5 fractional works · 18.6% of its workMolecular Biology: 2 fractional works · 7.6% of its workCancer Research: 2 fractional works · 7.1% of its workGenetics: 1 fractional works · 2.5% of its workEndocrinology: 0 fractional works · 0.6% of its workBiochemistry: 0 fractional works · 0.3% of its workClinical Biochemistry: 0 fractional works · 0.3% of its workSmaller subfields together: 0 fractional works · 0.1% of its workPharmacology, Toxicology and Pharmaceutics: 1 fractional works · 3.5% of its workPharmacology: 1 fractional works · 2.2% of its workPharmaceutical Science: 0 fractional works · 1.3% of its workNeuroscience: 1 fractional works · 2.0% of its workCellular and Molecular Neuroscience: 0 fractional works · 1.9% of its workSmaller subfields together: 0 fractional works · 0.2% of its workImmunology and Microbiology: 0 fractional works · 1.6% of its workImmunology: 0 fractional works · 1.6% of its workAgricultural and Biological Sciences: 0 fractional works · 0.5% of its workFood Science: 0 fractional works · 0.3% of its workPlant Science: 0 fractional works · 0.3% of its workPhysical Sciences: 3 fractional works · 13.0% of its workComputer Science: 1 fractional works · 4.6% of its workArtificial Intelligence: 1 fractional works · 4.6% of its workMathematics: 1 fractional works · 3.9% of its workStatistics and Probability: 1 fractional works · 3.9% of its workEngineering: 0 fractional works · 2.0% of its workBiomedical Engineering: 0 fractional works · 2.0% of its workEnvironmental Science: 0 fractional works · 1.8% of its workHealth, Toxicology and Mutagenesis: 0 fractional works · 1.3% of its workEcology: 0 fractional works · 0.5% of its workChemistry: 0 fractional works · 0.7% of its workSpectroscopy: 0 fractional works · 0.4% of its workOrganic Chemistry: 0 fractional works · 0.3% of its workSocial Sciences: 3 fractional works · 11.4% of its workEconomics, Econometrics and Finance: 3 fractional works · 11.0% of its workEconomics and Econometrics: 3 fractional works · 11.0% of its workPsychology: 0 fractional works · 0.4% of its workApplied Psychology: 0 fractional works · 0.2% of its workSmaller subfields together: 0 fractional works · 0.2% of its workALL ITS WORKReataPharmaceuticals…26fractional works, 2022-now
Life Sciences26%Physical Sciences13%Health Sciences49%Social Sciences11%

Each ring splits the one inside it: the four domains of science, their fields, their subfields. Size is fractional works in 2022-now. Every slice is a page; the interactive view zooms down to single topics and colours each by how much more of it this institution does than the world.

Its 4 domains and 14 fields, with their numbers
    1. Medicine1248.7%
    2. Health Professions00.7%
    1. Biochemistry, Genetics and Molecular Biology518.6%
    2. Pharmacology, Toxicology and Pharmaceutics13.5%
    3. Neuroscience12.0%
    4. Immunology and Microbiology01.6%
    5. Agricultural and Biological Sciences00.5%
    1. Computer Science14.6%
    2. Mathematics13.9%
    3. Engineering02.0%
    4. Environmental Science01.8%
    5. Chemistry00.7%
    1. Economics, Econometrics and Finance311.0%
    2. Psychology00.4%
All of science, and how each field's share has moved since 1950: the Science domain explorer

Field profile

Location quotient across every field it publishes in: outside the ring is more than an institution of this size would be expected to publish, inside it is less.

Agricultural and Biological Sciences: 0.11× its world share, 0 worksAgricultural and Bio…Biochemistry, Genetics and Molecular Biology: 3.49× its world share, 5 worksBiochemistry, Geneti…Immunology and Microbiology: 1.57× its world share, 0 worksImmunology and Micro…Neuroscience: 1.24× its world share, 0 worksNeurosciencePharmacology, Toxicology and Pharmaceutics: 9.85× its world share, 1 worksPharmacology, Toxico…Chemistry: 0.48× its world share, 0 worksChemistryComputer Science: 0.59× its world share, 1 worksComputer ScienceEngineering: 0.13× its world share, 0 worksEngineeringEnvironmental Science: 0.37× its world share, 0 worksEnvironmental ScienceMathematics: 3.32× its world share, 1 worksMathematicsHealth Professions: 0.25× its world share, 0 worksHealth ProfessionsMedicine: 2.53× its world share, 12 worksMedicineEconomics, Econometrics and Finance: 5.15× its world share, 3 worksEconomics, Econometr…Psychology: 0.14× its world share, 0 worksPsychology1×world share
more than its size predictsabout as predictedless

Rings at 0.5×, 1× and 2×. Widest outward: Pharmacology, Toxicology and Pharmaceutics, 9.8×. Every wedge is a field page.

All 14 fields, with their numbers
  1. Pharmacology, Toxicology and Pharmaceutics9.85×1 works
  2. Economics, Econometrics and Finance5.15×3 works
  3. Biochemistry, Genetics and Molecular Biology3.49×5 works
  4. Mathematics3.32×1 works
  5. Medicine2.53×12 works
  6. Immunology and Microbiology1.57×0 works
  7. Neuroscience1.24×0 works
  8. Computer Science0.59×1 works
  9. Chemistry0.48×0 works
  10. Environmental Science0.37×0 works
  11. Health Professions0.25×0 works
  12. Psychology0.14×0 works
  13. Engineering0.13×0 works
  14. Agricultural and Biological Sciences0.11×0 works

Who are the top researchers at Reata Pharmaceuticals (United States)?

Ranked on the quality score, Colin J. Meyer, Melanie P. Chin and Scott A. Reisman lead among researchers whose main affiliation is Reata Pharmaceuticals (United States).

  1. 1 Colin J. Meyer United States · #238,122 worldwide 6.9k citations · 124 works
  2. 2 Melanie P. Chin United States · #672,378 worldwide 3k citations · 108 works
  3. 3 Scott A. Reisman United States · #690,007 worldwide 2.4k citations · 40 works
  4. 4 Angie Goldsberry United States · #736,734 worldwide 2.2k citations · 46 works
  5. 5 Megan L. O’Grady United States · #839,680 worldwide 915 citations · 15 works
  6. 6 W. Christian Wigley United States · #842,450 worldwide 2.6k citations · 44 works
  7. 7 Deborah A. Ferguson United States · #1,007,128 worldwide 1.7k citations · 39 works
  8. 8 Joel W. Proksch United States · #3,835,975 worldwide 1.1k citations · 42 works
All ranked researchers at Reata Pharmaceuticals (United States)

What are the most cited papers from Reata Pharmaceuticals (United States)?

The most cited paper from Reata Pharmaceuticals (United States) is "Therapeutic targeting of the NRF2 and KEAP1 partnership in chronic diseases" (Antonio Cuadrado, Ana Isabel Rojo, Geoffrey Wells et al., 2019), with 1,477 citations. Next come "Bardoxolone Methyl in Type 2 Diabetes and Stage 4 Chronic Kidney Disease" (1,021) and "Bardoxolone Methyl and Kidney Function in CKD with Type 2 Diabetes" (886).

Most cited papers
#PaperReleasedCitations
1 Therapeutic targeting of the NRF2 and KEAP1 partnership in chronic diseases Antonio Cuadrado, Ana Isabel Rojo, Geoffrey Wells et al. · Nature Reviews Drug Discovery ReviewOpen access 4 Jan 2019 1,477
2 Bardoxolone Methyl in Type 2 Diabetes and Stage 4 Chronic Kidney Disease Dick de Zeeuw, Tadao Akizawa, Paul Audhya et al. · New England Journal of Medicine Open access 9 Nov 2013 1,021
3 Bardoxolone Methyl and Kidney Function in CKD with Type 2 Diabetes Pablo E. Pérgola, Philip Raskin, Robert Daniel Toto et al. · New England Journal of Medicine Open access 24 Jun 2011 886
4 Targeting the transcription factor Nrf2 to ameliorate oxidative stress and inflammation in chronic kidney disease Stacey Ruiz, Pablo E. Pérgola, Richard A. Zager et al. · Kidney International Open access 16 Jan 2013 722
5 Synthetic lethal screen identification of chemosensitizer loci in cancer cells Angelique W. Whitehurst, Brian O. Bodemann, Jessica Cardenas et al. · Nature Apr 2007 480
All 60 most cited papers, with filters and sorting

Which keywords describe research at Reata Pharmaceuticals (United States)?

By fractional works in 2022-now, weighted toward what it does more of than the world: Targeted Therapy, Chemotherapy, Precision Medicine, Cancer, Clinical Trials, Biomarkers, Genomic Instability and Cancer Genomics.

▲ more of its work than of the world's◆ about the world's share▼ less than the world's

Size is fractional works in 2022-now in the topics tagged with each word; colour is the word's share of this institution's work against its share of the world's. The 28 words are chosen for being large and distinctive. Each links to the topic it comes from most.

All 28 words, with their numbers
  1. Targeted Therapy3▲ 50×4 topics
  2. Chemotherapy3▲ 15×10 topics
  3. Precision Medicine3▲ 21×6 topics
  4. Cancer2▲ 7.4×12 topics
  5. Biomarkers2▲ 12×7 topics
  6. Clinical Trials2▲ 13×8 topics
  7. Quality of Life2▲ 5.6×4 topics
  8. Cancer Genomics2▲ 96×1 topic
  9. Genomic Instability2▲ 62×2 topics
  10. Inflammation2▲ 3.3×9 topics
  11. Mutational Signatures2▲ 96×1 topic
  12. Cost-effectiveness Analysis2▲ 82×1 topic
  13. Health Utility Measures2▲ 82×1 topic
  14. Predictive Modeling2▲ 23×2 topics
  15. Deep Learning2▲ 1.70×3 topics
  16. Healthcare2▲ 5.0×3 topics
  17. Immunotherapy2▲ 7.8×10 topics
  18. Antioxidant1▲ 7.7×3 topics
  19. Tumor Microenvironment1▲ 11×4 topics
  20. Cost of Care1▲ 149×1 topic
  21. Electronic Health Records1▲ 44×1 topic
  22. Financial Toxicity1▲ 149×1 topic
  23. Patient Similarity1▲ 69×1 topic
  24. Antiviral1▲ 56×2 topics
  25. Breast Cancer1▲ 18×5 topics
  26. Epidemiology1◆ 1.09×9 topics
  27. Medication Adherence1▲ 75×1 topic
  28. Treatment Adherence1▲ 143×1 topic

Which research topics does Reata Pharmaceuticals (United States) publish most on?

By volume in 2022-now: Cancer Genomics and Diagnostics, Health Systems, Economic Evaluations, Quality of Life, Economic and Financial Impacts of Cancer and Machine Learning in Healthcare.

Cancer Genomics and Diagnostics: 2 fractional worksHealth Systems, Economic Evaluations, Quality of Life: 2 fractional worksEconomic and Financial I…1Economic and Financial Impacts of Cancer: 1 fractional worksMachine Learning in Heal…1Machine Learning in Healthcare: 1 fractional worksMedication Adherence and Compliance: 1 fractional worksCancer Immunotherapy and Biomarkers: 1 fractional worksNatural product bioactiv…1Natural product bioactivities and synthesis: 1 fractional worksLung Cancer Treatments and Mutations: 1 fractional worksEthics in Clinical Research: 0 fractional worksMolecular Communication and Nanonetworks: 0 fractional works
Cancer ResearchEconomics and EconometricsArtificial IntelligenceFamily Practice5 others

Area is fractional works; colour is the subfield each topic belongs to.

  1. 1 Cancer Genomics and Diagnostics Cancer Research 2 works
  2. 2 Health Systems, Economic Evaluations, Quality of Life Economics and Econometrics 2 works
  3. 3 Economic and Financial Impacts of Cancer Economics and Econometrics 1 works
  4. 4 Machine Learning in Healthcare Artificial Intelligence 1 works
  5. 5 Medication Adherence and Compliance Family Practice 1 works
  6. 6 Cancer Immunotherapy and Biomarkers Oncology 1 works
  7. 7 Natural product bioactivities and synthesis Molecular Biology 1 works
  8. 8 Lung Cancer Treatments and Mutations Pulmonary and Respiratory Medicine 1 works
  9. 9 Ethics in Clinical Research Public Health, Environmental and Occupational Health 0 works
  10. 10 Molecular Communication and Nanonetworks Biomedical Engineering 0 works

How open and international is its research?

Against the world's own shares: the tick on each track. Both are shares of its output, so they sit on one scale and can be read against each other as well as against the world.

openly available47.3%not open52.7%

World: 40% of research is openly available.

with international co-authors19.3%domestic only80.7%

World: 18% is written across borders.

How has Reata Pharmaceuticals (United States)'s research output changed?

Output in 2022-2025 was 14% higher than in 2018-2021.

still counting200020102020
grewheldshrank

The same series as a ribbon: one cell per year, darker for more. The line above answers how much; this answers when.

Its share of all research

Growing output can still be a shrinking share: all of science grows. This is Reata Pharmaceuticals (United States) as a percentage of every work published that year, 0.000091% in 2024.

still counting0.00010%0.00020%0.00030%Reata Pharmaceuticals (United States)0.000015% in 2025200020102020

Fractional works of Reata Pharmaceuticals (United States) over all fractional works that year. How the balance of science has shifted.

Other research institutions in Irving

All research institutions in Irving

Research measures only: rankings here say nothing about teaching, admissions or student experience. Comparable institutions and collaboration partners have tabs of their own, above.

Discussion

Ask a question or share a note about Reata Pharmaceuticals (United States). Keep it to the research: no personal attacks, advertising or links. Any reader can report a post, which collapses it for everyone until it is opened.